Title:
ＣＣＲ８阻害剤を使用してＴｒｅｇｓを標的とする方法および組成物
Document Type and Number:
Japanese Patent JP2023540661
Kind Code:
A
Abstract:
本発明は、ＣＣＲ８阻害剤としての式（Ｉ）の化合物を提供し、これは、腫瘍特異的調節性Ｔ細胞を標的とするＣＣＲ８阻害剤を使用して、癌を治療または予防するために使用されることができる。式（Ｉ）：JPEG2023540661000478.jpg2877【選択図】なし
Inventors:
fan, guo fan
Yang, Hongyu
Fung, Kin Chiu
One, Zhenfei
Yang, Hongyu
Fung, Kin Chiu
One, Zhenfei
Application Number:
JP2022581326A
Publication Date:
September 26, 2023
Filing Date:
July 03, 2020
Export Citation:
Assignee:
NANJING IMMUNOPHAGE BIOTECH CO., LTD.
International Classes:
C07D211/28; A61K31/145; A61K31/351; A61K31/353; A61K31/397; A61K31/40; A61K31/401; A61K31/403; A61K31/4035; A61K31/4045; A61K31/41; A61K31/416; A61K31/4184; A61K31/4192; A61K31/423; A61K31/426; A61K31/437; A61K31/438; A61K31/439; A61K31/445; A61K31/4453; A61K31/4458; A61K31/4462; A61K31/4465; A61K31/4523; A61K31/4535; A61K31/454; A61K31/4545; A61K31/47; A61K31/4706; A61K31/472; A61K31/4725; A61K31/495; A61K31/496; A61K31/498; A61K31/517; A61K31/5375; A61K31/538; A61K31/55; A61K31/551; A61K31/553; A61K31/63; A61P29/00; A61P35/00; A61P35/02; A61P43/00; C07C311/19; C07C311/29; C07C311/46; C07C311/51; C07C311/58; C07C381/10; C07D205/04; C07D207/09; C07D207/16; C07D209/08; C07D209/10; C07D209/44; C07D209/48; C07D211/60; C07D211/62; C07D215/36; C07D215/42; C07D217/02; C07D217/06; C07D217/22; C07D217/24; C07D221/20; C07D223/16; C07D231/56; C07D235/08; C07D235/26; C07D235/30; C07D239/86; C07D239/96; C07D243/08; C07D249/06; C07D257/04; C07D263/58; C07D265/30; C07D265/36; C07D267/14; C07D277/28; C07D277/82; C07D295/135; C07D309/04; C07D311/04; C07D401/12; C07D405/04; C07D405/12; C07D409/12; C07D417/12; C07D453/02; C07D471/04; C07D487/08
Attorney, Agent or Firm:
Patent Attorney Corporation Sakamoto International Patent and Trademark Office
Previous Patent: Stress assessment and management techniques
Next Patent: GLP-1R agonist peptides with reduced activity
Next Patent: GLP-1R agonist peptides with reduced activity